Breast Cancer Drug Gets a Unanimous Thumbs Down - ScienceInsider
30 Junho 2011
An advisory committee to the U.S. Food and Drug Administration (FDA) sided this afternoon with the agency, agreeing in a unanimous vote, 6-0, that the drug Avastin should not be approved for breast cancer. Although FDA doesn't have to side with its advisory committee, in this case it's likely to do so since it made a similar decision back in December. Agency officials reiterated their case against Avastin yesterday. Read more:Breast Cancer Drug Gets a Unanimous Thumbs Down - ScienceInsider